KR20140014294A - 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법 - Google Patents

유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법 Download PDF

Info

Publication number
KR20140014294A
KR20140014294A KR1020137034233A KR20137034233A KR20140014294A KR 20140014294 A KR20140014294 A KR 20140014294A KR 1020137034233 A KR1020137034233 A KR 1020137034233A KR 20137034233 A KR20137034233 A KR 20137034233A KR 20140014294 A KR20140014294 A KR 20140014294A
Authority
KR
South Korea
Prior art keywords
prostate
controlled release
flutamide
active substance
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137034233A
Other languages
English (en)
Korean (ko)
Inventor
한스 레너나스
보 레너나스
조나스 휴고썬
니클라스 악센
Original Assignee
리드스 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리드스 에이비 filed Critical 리드스 에이비
Publication of KR20140014294A publication Critical patent/KR20140014294A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137034233A 2005-03-31 2006-03-31 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법 Ceased KR20140014294A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200500452 2005-03-31
DKPA200500452 2005-03-31
PCT/EP2006/003194 WO2006103112A2 (en) 2005-03-31 2006-03-31 Method for treating prostate diseases based on local delivery of active substances

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077022037A Division KR101380402B1 (ko) 2005-03-31 2006-03-31 전립선 관련 질병 치료용의 키트

Publications (1)

Publication Number Publication Date
KR20140014294A true KR20140014294A (ko) 2014-02-05

Family

ID=35044589

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137034233A Ceased KR20140014294A (ko) 2005-03-31 2006-03-31 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법
KR1020077022037A Expired - Fee Related KR101380402B1 (ko) 2005-03-31 2006-03-31 전립선 관련 질병 치료용의 키트

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077022037A Expired - Fee Related KR101380402B1 (ko) 2005-03-31 2006-03-31 전립선 관련 질병 치료용의 키트

Country Status (17)

Country Link
US (1) US8936809B2 (cg-RX-API-DMAC10.html)
EP (1) EP1865924B1 (cg-RX-API-DMAC10.html)
JP (2) JP5635231B2 (cg-RX-API-DMAC10.html)
KR (2) KR20140014294A (cg-RX-API-DMAC10.html)
CN (1) CN101160116B (cg-RX-API-DMAC10.html)
AU (1) AU2006228675B2 (cg-RX-API-DMAC10.html)
CA (1) CA2602776C (cg-RX-API-DMAC10.html)
DK (1) DK1865924T3 (cg-RX-API-DMAC10.html)
ES (1) ES2557988T3 (cg-RX-API-DMAC10.html)
HU (1) HUE026158T2 (cg-RX-API-DMAC10.html)
IL (1) IL185690A0 (cg-RX-API-DMAC10.html)
MX (1) MX2007011908A (cg-RX-API-DMAC10.html)
NO (1) NO338679B1 (cg-RX-API-DMAC10.html)
PL (1) PL1865924T3 (cg-RX-API-DMAC10.html)
RU (1) RU2404747C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006103112A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200708066B (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법
MX2011005243A (es) * 2008-11-27 2011-08-08 Lidds Ab Uso de carboximetilcelulosa para controlar la eyectabilidad y el tiempo de solidificacion de las composiciones que comprenden una o mas ceramicas biorreabsorbibles.
AU2012240131B2 (en) * 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
RU2519407C2 (ru) * 2011-09-21 2014-06-10 Виктор Павлович Горелов Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
WO2016028774A1 (en) 2014-08-19 2016-02-25 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
JP6758325B2 (ja) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2020061291A1 (en) * 2018-09-20 2020-03-26 Biovena Science, Llc Flutamide microsphere-based arterial embolization for treating prostate disorders
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11338119B2 (en) * 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) * 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CA3171976A1 (en) * 2020-03-20 2021-09-23 Carlos Schuler Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
EP4469108A1 (en) * 2022-01-29 2024-12-04 Resurge Therapeutics, Inc. Benign prostatic hyperplasia treatment system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
US5795330A (en) 1996-10-10 1998-08-18 Etex Corporation Mixing device
CA2268156C (en) * 1996-10-16 2007-05-29 Etex Corporation Bioceramic compositions
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US5972384A (en) * 1997-10-01 1999-10-26 University Of Maryland, Baltimore Use of biologically active glass as a drug delivery system
CA2378486A1 (en) 1999-08-05 2001-02-15 Takashi Kurasawa Osteogenesis promoter sustained-release paste
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
US8404681B2 (en) * 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
GB0307082D0 (en) * 2003-03-27 2003-04-30 Gyne Ideas Ltd Drug delivery device and method
JP4927535B2 (ja) * 2003-04-03 2012-05-09 ジェシー エル エス オウ 腫瘍を標的指向化する薬物を封入した粒子
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
PL1680089T3 (pl) * 2003-10-22 2014-03-31 Lidds Ab Kompozycja zawierająca biodegradowalną ceramikę hydratującą do kontrolowanego dostarczania leków
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법

Also Published As

Publication number Publication date
EP1865924B1 (en) 2015-12-09
RU2007140243A (ru) 2009-05-10
US8936809B2 (en) 2015-01-20
JP2013067639A (ja) 2013-04-18
WO2006103112A3 (en) 2006-12-21
NO20075490L (no) 2008-01-02
AU2006228675B2 (en) 2012-05-17
KR20080002776A (ko) 2008-01-04
EP1865924A2 (en) 2007-12-19
DK1865924T3 (en) 2016-02-29
WO2006103112A2 (en) 2006-10-05
ZA200708066B (en) 2016-07-27
CN101160116A (zh) 2008-04-09
US20080286205A1 (en) 2008-11-20
NO338679B1 (no) 2016-09-26
PL1865924T3 (pl) 2016-06-30
CN101160116B (zh) 2011-12-07
JP2008534546A (ja) 2008-08-28
HUE026158T2 (en) 2016-05-30
MX2007011908A (es) 2008-02-07
CA2602776C (en) 2013-10-22
JP5635231B2 (ja) 2014-12-03
RU2404747C2 (ru) 2010-11-27
CA2602776A1 (en) 2006-10-05
ES2557988T3 (es) 2016-02-01
KR101380402B1 (ko) 2014-04-02
AU2006228675A1 (en) 2006-10-05
IL185690A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
KR101380402B1 (ko) 전립선 관련 질병 치료용의 키트
JP6445123B2 (ja) 癌を治療するための方法及び組成物
JP6509405B2 (ja) アンドロゲン受容体調節剤及びその使用
Flaig et al. A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer
JP6938462B2 (ja) 治療用化合物の脳への一方向送達のためのインプラント組成物
EP2523653B1 (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
AU2386301A (en) Fulvestrant formulation
KR20090060306A (ko) 비타민 d 화합물 및 추가 치료제, 및 그를 함유하는 조성물을 투여하는 것을 포함하는, 암을 치료하는 방법
EP4340824A1 (en) Methods and compositions for inducing brown adipogenesis
KR101563069B1 (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
Cheung et al. In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations
CN1168448C (zh) 预防和/或治疗乳腺癌的含类固醇芳香酶抑制剂的药物
JP2020530031A (ja) 前立腺癌治療における新しいアジュバント療法
JP2008538580A (ja) 活性ビタミンd化合物またはその模倣体による、化学療法または放射線療法と関連する肺疾患の治療、予防、および改善
US20250040935A1 (en) Fabrication of radiopaque resorbable hydrogel beads via microfluidics for catheter embolization applications
Czarnywojtek et al. A new hypothesis in the treatment of recurrent glioblastoma multiforme (GBM). Part 2: Is there an alternative therapy option in recurrent GM when all standard treatments have been exhausted
OA19845A (en) Injectable composition.
Hermosillo-Rodriguez et al. Treatment of Metastatic Cancer: Hormonal Agents, Chemotherapy, Immune Modulation, and Radiopharmaceuticals
Goya et al. Local injection of a sustained‐release antiandrogen formulation into a target prostatic site: an experimental study
KR20200074037A (ko) 두타스테리드를 포함하는 조성물
Stevens et al. Medical Therapy for Meningiomas

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131223

Application number text: 1020077022037

Filing date: 20070927

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140106

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140307

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140731

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140307

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I